Induced by Anthracyclines

Prospective Evaluation of Early Cardiac Damage Induced by Epirubicin-Containing Adjuvant Chemotherapy and Locoregional Radiotherapy in Breast Cancer Patients

By M.T. Meinardi, D.J. van Veldhuisen, J.A. Gietema, W.V. Dolsma, F. Boomsma, M.P. van den Berg, C. Volkers, J. Haaksma, E.G.E. de Vries, D.Th. Sleijfer, W.T.A. van der Graaf

From the Departments of Medical Oncology, Cardiology, and Radiation Oncology, University Hospital, Groningen; and Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands.

Address reprint requests to W.T.A. van der Graaf, MD, PhD, Department of Medical Oncology, University Hospital, PO Box 30.001, 9700 RB Groningen, the Netherlands; email: w.t.a. van.der.graaf@int.azg.nl.

PURPOSE: To evaluate prospectively the cardiotoxic effects of epirubicin-containing adjuvant chemotherapy in breast cancer patients.

PATIENTS AND METHODS: Patients (median age, 46 years; range, 28 to 55 years) were treated with five cycles of fluorouracil, epirubicin (90 mg/m2), and cyclophosphamide (FEC) (group I, n = 21) or with four cycles of FEC followed by high-dose chemotherapy consisting of cyclophosphamide, thiotepa, and carboplatin (group II, n = 19). Locoregional radiotherapy was applied subsequently. Cardiac evaluation was performed before chemotherapy (T0), 1 month after chemotherapy, 1 month after radiotherapy (T2), and 1 year after start of chemotherapy (T3). Left ventricular ejection fraction (LVEF) was determined by radionuclide ventriculography and diastolic function by echocardiography.

Autonomic function was assessed by 24-hour ECG registration for heart rate variability (HRV) analysis. Time-corrected QT (QTc) was assessed and N-terminal atrial natriuretic peptide (NT-ANP) and brain natriuretic peptide (BNP) were measured as biochemical markers of cardiac dysfunction.

RESULTS: No patient developed overt congestive heart failure (CHF) and the mean LVEF declined from 0.61 at T0 to 0.54 at T3 (P = .001), resulting in an LVEF below 0.50 (range, 0.42 to 0.49) in 17% of the patients, whereas 28% had a decline of more than 0.10. Plasma NT-ANP levels increased gradually from 237 pmol/L at T0 to 347 pmol/L at T3 (P < .01), whereas plasma BNP levels increased from 2.9 pmol/L to 5.1 pmol/L (P = .04).

Mean QTc increased from 406 msec at T0 to 423 msec at T3 (P < .01). No persistent alterations were found in diastolic function and HRV.

CONCLUSION: Relatively low doses of epirubicin in adjuvant chemotherapy for breast cancer results in mild subclinical myocardial damage demonstrated by a decline in LVEF, an increase in natriuretic peptide levels, and an increase in QTc, which may indicate a long-term risk of CHF.

Journal of Clinical Oncology, Vol 19, Issue 10 (May), 2001: 2746-2753


Doctors' Guide Review of this Study

May 2001

Cardiac Effects:Adj Chemo & Radiation

Ann Oncol, 1994

High Incidence of Central Nervous System Involvement

Annals of Oncology, May 2001

Effects of Dose-Intensive Chemo/Radiotherapy

Breast Cancer Research & Treatment, 9/01

Cardiotoxic Potential of Anti-Emetics (5-HT3)

The Oncologist, 2/02

Periodontal Infection & High-dose Chemo

Supportive Cancer Care, issue to be published, 2002

Cardiac Peptide Gives Early Warning of Injury (Bca treatment)

Annals of Oncology, 4/02

Doxorubicin Riskier for the Heart

Cancer, 6/03

Ketotifen Alleviates Cardiotoxicity of Doxorubicin
Doxorubicin Cardiotoxicity: Early and Continual Damage
Anthracyclines & Topoll-2 8% of Users Benefit (BCa)
Chemotherapy Doesn't Help in Malignant Mesolthelioma
Gated Heart Test & Others  Before Chemo

Information from Toya 'Nukenut", 6/03

Gleevec Can Cause Heart Failure

Nature Medicine, 6/06

Long-Term Cardiac Trouble & Adjvt Chemotherapy

JCO, January 2001

Anthracycline Cardiotoxicity Needs Tracking for Years
Heart Treatment Helpful
Subclinical Late Cardio Problems w/Doxorubicin: Lymphoma
Doxorubicin , Cardio Damage, Vit C and SB203580
Cardiovascular

Am J Clinical Nutrition, 6/02

Dean Ornish, MD-on healthy eating-Heart/more
Systemic Inflammatory Response & Survival
CHD: Eat Fish, Take EPA/DHA, Flaxseed, Walnuts
Three Dietary Strategies:Prevent CHD
Cardiovascular Dis & MicronutriTher
Evaluation of Isphagula Husk (Pysillium)
Hormone Replacement & Antioxidants
Acetyl Cysteine /CardioEvents/Renal Failure
Randomized Trial Antioxidant Sup & Surg Pts
Use of Antioxidant Vitamins-Prevention:Meta-analysis
NIH Trial on Chelation Therapy
Low LDL cholesterol associated with increased cancer risk
Heart failure associated with sunitinib

Cancer, 2008


Remember we are NOT Doctors and have NO medical training.

This site is like an Encyclopedia - there are many pages, many links on many topics.

Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.